A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

ClinicalTrials.gov ID: NCT06439082

Public ClinicalTrials.gov record NCT06439082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 2, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises

Study identification

NCT ID: NCT06439082
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 315 participants

Conditions and interventions

Conditions

Sickle Cell Disease

Interventions

Crizanlizumab Biological
Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range: 12 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 23, 2024
Primary completion: Mar 22, 2029
Completion: Apr 18, 2030
Last update posted: Apr 30, 2026

2024 – 2030

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
University Of Alabama	Birmingham	Alabama	35233	Recruiting
Childrens National Hospital	Washington D.C.	District of Columbia	20010	Recruiting
University of Florida	Jacksonville	Florida	32209	Recruiting
Augusta University Georgia	Augusta	Georgia	30912	Recruiting
WCG Sonar Clinical Research	Riverdale	Georgia	30274	Recruiting
Norton Children s Hospital	Louisville	Kentucky	40202	Recruiting
The Johns Hopkins University School of Medicine	Baltimore	Maryland	21205	Recruiting
Southern Specialty Research	Flowood	Mississippi	39232	Recruiting
Childrens Hospital at Montefiore	The Bronx	New York	10467	Recruiting
East Carolina University	Greenville	North Carolina	27834	Recruiting
Wake Forest University Baptist Medical Center	Winston-Salem	North Carolina	27157	Recruiting
Spoknwrdclinicaltrials	Easton	Pennsylvania	18045	Recruiting
U of TX Health Science Ct	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06439082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06439082 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →